Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common stock, par value $0.001 per share
-
Shares outstanding
-
5.43M
-
Number of holders
-
36
-
Total 13F shares, excl. options
-
4.97M
-
Shares change
-
-1.55M
-
Total reported value, excl. options
-
$25.4M
-
Value change
-
-$7.62M
-
Put/Call ratio
-
3.39
-
Number of buys
-
17
-
Number of sells
-
-24
-
Price
-
$5.11
Significant Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q3 2021
59 filings reported holding APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share as of Q3 2021.
Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.97M shares
of 5.43M outstanding shares and own 91.45% of the company stock.
Largest 10 shareholders include Versant Venture Management, LLC (1.26M shares), VANGUARD GROUP INC (717K shares), Redmile Group, LLC (695K shares), BlackRock Inc. (354K shares), KENNEDY CAPITAL MANAGEMENT, INC. (342K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (200K shares), GEODE CAPITAL MANAGEMENT, LLC (198K shares), JPMORGAN CHASE & CO (186K shares), MORGAN STANLEY (185K shares), and GOLDMAN SACHS GROUP INC (145K shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.